Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial-Reference-Cited by-同舟云学术

Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial

Published:2017-03 Issue:3 Volume:18 Page:297-311
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Zelenetz Andrew D,Barrientos Jacqueline C,Brown Jennifer R,Coiffier Bertrand,Delgado Julio,Egyed Miklós,Ghia Paolo,Illés Árpád,Jurczak Wojciech,Marlton Paula,Montillo Marco,Morschhauser Franck,Pristupa Alexander S,Robak Tadeusz,Sharman Jeff P,Simpson David,Smolej Lukáš,Tausch Eugen,Adewoye Adeboye H,Dreiling Lyndah K,Kim Yeonhee,Stilgenbauer Stephan,Hillmen Peter

Publisher

Elsevier BV

Subject

Oncology

Reference20 articles.

1. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997;Grever;J Clin Oncol,2007

2. TP53 mutation and survival in chronic lymphocytic leukemia;Zenz;J Clin Oncol,2010

3. Genomic aberrations and survival in chronic lymphocytic leukemia;Dohner;N Engl J Med,2000

4. Chronic lymphocytic leukemia: 2015 update on diagnosis, risk stratification, and treatment;Hallek;Am J Hematol,2015

5. Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemia;Blunt;Leuk Res Rep,2015

Cited by 219 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The efficacy and safety of PI3K and AKT inhibitors for patients with cancer: A systematic review and network meta-analysis;European Journal of Pharmacology;2024-11

2. Holding the therapy in CLLp53: mechanisms to achieve durable responses;Anti-Cancer Drugs;2024-08-09

3. PI3K Inhibitors in Hematology: When One Door Closes…;Clinical Cancer Research;2024-07-05

4. Clinical Mycology Today: Emerging Challenges and Opportunities;Open Forum Infectious Diseases;2024-06-27

5. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024;Journal of the National Comprehensive Cancer Network;2024-04